Two studies by HSCI scientists advance our understanding of cancer
Two new studies by Harvard Stem Cell Institute (HSCI) scientists give important insights into lung and liver cancers, and have potential implications for cancer treatment.
Carla Kim, Ph.D., HSCI Executive Committee member, has identified a caveat for a...
The Harvard Department of Stem Cell and Regenerative Biology (HSCRB) invites applications for Pilot Grant funding for 2019 under the NIH-funded P01 grant “Dissecting the establishment and regulation of human pluripotency” (PI Alexander Meissner). The purpose of this funding program is to provide resources for proof-of-concept studies. These pilot grants are intended to increase our understanding of the basic biology of human pluripotent cells and their utility for translational...
Biotech company Moderna, co-founded by HSCI scientist Derrick Rossi, is set to bring a new class of treatments to patients.
Summary
Derrick Rossi’s research into using mRNA as a new kind of therapeutic was initially supported by HSCI seed funding, and gave rise to biotech companyModerna Therapeutics.
Moderna’s public offering of $600 million is the largest ever of a venture-capital-backed biotechnology company, reflecting the potential of its new technology: mRNA therapeutics
Moderna’s success in creating therapies that will benefit patients reflects the crucial role of HSCI in enabling early-stage, high-risk research.
Markus Frank and his colleagues are reprogramming skin cells with the goal of giving people back their sight.
Seed funding from HSCI led Markus Frank and his colleagues to discover that the cell surface molecule ABCB5 can be used to identify limbal stem cells, which regenerate the cornea.
The team is developing ABCB5-positive cell therapy as a treatment for vision loss due to limbal stem cell deficiency.
Markus Frank, M.D., co-leader of the HSCI Skin Program, is reprogramming stem cells from the skin...
The Harvard Stem Cell Institute (HSCI) Invites applications for seed grant funding for its 2019 cycle. The purpose of this program is to provide funding for innovative projects in the field of stem cell and regenerative biology. As was the case last year, the HSCI strongly encourages proposals with a translational focus, or which are otherwise poised to accelerate the development of new stem cell-based therapies or cures. However, proposals at all stages of development are welcome. The HSCI intends to award up to ten grants in response to this call for proposals, contingent upon the...
Clifford Woolf wants to reboot drug discovery to find a new way to treat pain: effectively and responsibly.
Woolf’s goal is to stop the opioid crisis by rejecting the conventional approach to drug discovery and developing painkillers that do not harm people or communities.
He is using stem cells to create models of pain, outside the body and in a dish, that can be used to screen for drugs swiftly and on a large scale.
The new approach requires ‘all hands’: expertise, equipment, and collaboration in stem...
Mario Suva and Ramesh Shivdasani are tackling some of the toughest, meanest cancers to clear a path to better treatments.
Suva and Shivdasani are using every approach in their arsenal to figure out what makes cancer cells arise from healthy tissue.
Armed with enough new knowledge about how cancer arises, they want to take truer aim at cancer cells, the cancer cell lineage, and factors that make cells go awry.
Their new approach to cancer management would combine gene and cell therapies to kill the cancer...
HSCI physician-scientists Daniel Tenen and Li Chai want to turn off a gene to stop cancer without poisoning the patient.
The ideal cancer drug would harm cancer cells without hurting normal cells.
In their quest to discover one good therapy, HSCI scientists Dan Tenen and Li Chai have zeroed in on SALL4, a gene that is essential for growth in both embryos and cancers.
